Kerschbaum, Julia
Rudnicki, Michael
Dzien, Alexander
Dzien-Bischinger, Christine
Winner, Hannes
Heerspink, Hiddo Lambers
Rosivall, László
Wiecek, Andrzej
Mark, Patrick B.
Eder, Susanne
Denicolò, Sara
Mayer, Gert
Funding for this research was provided by:
Innovative Medicines Initiative 2 Joint undertaking
AbbVie Deutschland
Article History
Received: 23 July 2020
Accepted: 21 October 2020
First Online: 12 November 2020
Competing interests
: GM reports grants from Abbvie, during the conduct of the study; grants and personal fees from Abbvie, personal fees from Böhringer Ingelheim, personal fees from Novo Nordisk, outside the submitted work; SD reports grants from Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreement No. 115974 (BEAt-DKD) during the conduct of the study. PBM reports personal fees and non-financial support from Vifor, personal fees from Astrazeneca, grants from Boehringer Ingelheim, personal fees and non-financial support from Pharmacosmos, personal fees from Janssen, personal fees from Novartis, personal fees from Pfizer, personal fees from Bristol Myers Squibb, personal fees and non-financial support from Napp, outside the submitted work; HLH reports other from Astra Zeneca, other from Astellas, other from Boehringer Ingelheim, other from Fresenius, other from Mitsubishi Tanabe, other from Janssen, other from Mundipharma, other from Gilead, other from Abbvie, other from DIMERIX, outside the submitted work; JK, LR, MR, AD, CDB, SE, AW and HW declared no competing interests.